Scale-up complete for Alzheimer's candidate

Manufacturing scale-up is complete for Avanex Life Sciences' alzheimer's treatment. A Phase I clinical trial of AVANEX 2-73 is set to begin in early 2010.

Some two kilograms of the drug candidate were manufactured by Sweden-based Syntagon, a provider of synthetic organic chemistry services. The contract manufacturer developed a five-step synthetic procedure for production of the compound. In addition, it developed and evaluated analytical methods for the production process.

The compound uses sigma receptors to correct dysfunction in the mitochondria and ultimately protect cells from oxidative stress, which is believed to be an underlying cause of the disease, according to a company announcement.

- here's the announcement

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.